Kansai Medical University Hospital Administers First Patient Dose of DS1025 in Global Phase 1 Clinical Trial Sponsored by Daiichi Sankyo

Trial StartDS1025Neutral

AI Analysis

Summary

Kansai Medical University Hospital administered the first patient dose of DS1025, a potential first-in-class CD25-directed antibody drug conjugate, in a global Phase 1 trial sponsored by Daiichi Sankyo in advanced solid tumors. The dosing occurred on August 18, 2026.

Clinical Trial Data

Phase

Phase_1

Outcome Details

First patient worldwide dosed with DS1025, a potential first-in-class CD25-directed antibody drug conjugate, on August 18, 2026 at Kansai Medical University Hospital.

Importance:4/10

Sentiment:

0.20

Phase 1first patient dosedantibody drug conjugateCD25oncologysolid tumorsJapanDaiichi Sankyo

Related Companies

$DSKYF

Read the original article

Published by PR Newswire Pharma on October 19, 2026 12:44 PM

Read Original